ArticleJournal of functional biomaterials2025
Polycaprolactone/Doped Bioactive Glass Composite Scaffolds for Bone Regeneration.
Article in Journal of functional biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Critical-size bone defects do not heal spontaneously and require external support, making bone regeneration a central challenge in tissue engineering. Polymeric/ceramic composite scaffolds offer a promising approach to mimic the structural and biological properties of bone. In this study, we aimed to evaluate the effect of different doping oxides in bioactive glass (BG) on the performance of polycaprolactone (PCL)-based composite scaffolds for bone tissue engineering applications. Composite scaffolds were fabricated using solvent casting, hot pressing, and salt-leaching techniques, combining PCL with 25 wt% of BG or doped BG containing 4 mol% of tantalum, zinc, magnesium, or niobium oxides, and 1 mol% of copper oxide. The scaffolds were characterized in terms of morphology, mechanical properties, and in vitro biological performance. All scaffolds exhibited a highly porous, interconnected structure. Mechanical compression tests indicated that elastic modulus increased with ceramic content, while doping had no measurable effect. Cytotoxicity assays confirmed biocompatibility across all scaffolds. Among the tested materials, the Zn-doped BG/PCL scaffold uniquely supported cell adhesion and proliferation and significantly enhanced alkaline phosphatase (ALP) activity-an early marker of osteogenic differentiation-alongside the Nb-doped scaffold. These results highlight the Zn-doped BG/PCL composite as a promising candidate for bone regeneration applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.